Clinically, NAT10 overexpression correlates with reduced overall survival in advanced GC and confers cisplatin resistance (IC50 reduction by 60% upon knockdown) (18);USP15 (Ubiquitin-specific protease 15), a pivotal member of the ubiquitin-specific protease (USP) family (19, 20). Here, NAT10 is linked to gastric cancer.